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Phenazepam and etizolam were the first uncontrolled benzodiaze-
pines available for sale in the UK. Pyrazolam, flubromazepam and 
diclazepam are not used medicinally anywhere in the world; they are 
produced exclusively for the uncontrolled, recreational market. It is 
important to know whether potentially abused drugs like these can be 
detected in routine toxicological screening tests. The purpose of this 
study was to evaluate whether the Immunalysis Benzodiaz-epines 
ELISA kit could detect phenazepam, etizolam, pyrazolam, flu-
bromazepam, diclazepam and its metabolite delorazepam. Their 
cross-reactivity was assessed by comparing the absorbance of the 
drug with that of oxazepam, the reference standard. This study found 
that these uncontrolled benzodiazepines cross-react sufficiently to 
produce a positive result with the Immunalysis Benzodiazepine ELISA 
kit. Cross-reactivity ranged from 79 to 107% for phenazepam, 
etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam 
for-tified into blood. The results show that it is possible to detect these 
newer benzodiazepines with traditional forensic toxicology laboratory 
tools and it is important to include these benzodiazepines in the con-
firmation tests. 
 
 
Introduction 
 
Benzodiazepines are one of the most commonly used drugs in 
Scotland. The most commonly prescribed benzodiazepine in Scotland 
is diazepam. In the financial year 2013–2014, diazepam was 
dispensed 891,005 times. The second most dispensed benzo-
diazepine was temazepam, followed by nitrazepam. These figures 
include repeat prescriptions as well as prescriptions writ-ten in 
hospital that were dispensed within the community but not 
prescriptions dispensed within hospitals (1). Phenazepam was the 
first uncontrolled benzodiazepine to emerge on the UK recreational 
market; police seized phenazepam in white powder form in Scotland 
in October 2008. From 2008 to 2011, phenazepam was detected in 
blue pills seized in the UK; these pills often had markings that 
suggested they were being sold as diazepam (2). Phenazepam was 
subsequently controlled in the UK in 2012 (3). Phenazepam has been 
a prescribed drug in Russia since the 1970s for neurological 
disorders, epilepsy and alcohol withdrawal (4).  
Etizolam has been prescribed in Japan since 1983 for anxiety and 
used as a strong muscle relaxant. The drug was first reported to the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) in December 2011 after four blue tablets were seized 
from an individual in the UK who had purchased them online (5). 
Etizolam has become increasingly popular rec-reationally in the UK 
and remains unscheduled. Etizolam abuse has been reported as a 
problem in Japan (6).  
Pyrazolam emerged on the online recreational market in 2012. 
Unlike phenazepam and etizolam, it is not marketed by any pharma-
ceutical company anywhere in the world; therefore, it is considered 
 
as the first designer benzodiazepine produced for the legal market. 
Pyrazolam was first reported to the EMCDDA in August 2012 by 
Finnish Customs in Helsinki who seized 10 white tablets from an 
incoming item of mail in August 2011. A white tablet analyzed by 
TICTAC Communications in July 2012 is the first reported in-stance of 
pyrazolam in the UK (5). Pyrazolam’s structure can be thought of as a 
combination of alprazolam and bromazepam (7).  
The second designer benzodiazepine to appear on the legal market 
was flubromazepam in late 2012. Flubromazepam is structurally 
related to phenazepam; the chlorine atom in phena-zepam is 
substituted for fluorine in flubromazepam (8). Germany was the first to 
report flubromazepam to the EMCDDA; Germany reported 10 
capsules of flubromazepam collected in March 2013. In June 2013, 
the UK then reported a sample of 500 mg flubro-mazepam powder 
collected in April 2013 in Guernsey, which had been sent from the UK 
(5).  
Diclazepam emerged as a research chemical in 2013. It was first 
reported to the ECMDDA by the Department of Forensic Toxicology, 
the University Medical Center Freiburg, Germany, which analyzed 20 
diclazepam tablets. The UK reported a collec-tion of diclazepam 
samples bought online to the ECMDDA in September 2013 (5). 
Diclazepam has the structure of diazepam with an additional chlorine 
atom (see Figure 1) (9). Delorazepam, lorazepam and lormetazepam 
are active metabolites of diclaze-pam. These metabolites are 
prescription drugs in the UK with the exception of delorazepam.  
The purpose of this study was to evaluate whether the 
Immunalysis® Benzodiazepines ELISA kit ( part number: 214-0480) 
could detect phenazepam, etizolam, pyrazolam, flu-bromazepam, 
diclazepam and its metabolite delorazepam. Their cross-reactivity was 
assessed by comparing absorbance of the drug with that of 
oxazepam, the reference standard. 
 
Experimental 
 
Reagents  
Phenazepam, etizolam and oxazepam were purchased from Sigma-
Aldrich, UK. Pyrazolam and diclazepam were purchased from Chiron 
AS, Trondheim, Norway. Flubromazepam and delora-zepam were 
purchased from LGC Standards, Teddington, UK. The blank blood 
used was purchased from the Scottish National Blood Transfusion 
Service, Gartnaval Hospital, Glasgow, UK. The Immunalysis® 
Benzodiazepine ELISA kit and the PBS buffer (pH 7.0) were 
purchased from Alere Toxicology, Abingdon, UK. HiPerSolv Methanol 
was purchased from VWR International Ltd., Leicestershire, UK. 
 
Sample preparation  
Individual stock solutions containing 1 mg/mL of drugs were pre-pared 
in methanol. Oxazepam used for the cross-reactivity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The chemical structure of phenazepam, etizolam, pyrazolam, flubromazepam, 
diclazepam and delorazepam. 
 
 
 
 
comparison was also prepared at 1 mg/mL in methanol. Blank blood 
and PBS buffer were fortified with oxazepam at concentra-tions of 0, 
5, 10, 100 and 300 ng/mL, and these were used as cal-ibrators. 
These concentrations were chosen to cover a suitable range. 
Individual aliquots of blank blood were fortified with phe-nazepam, 
etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam at 
the same concentrations. All fortified blood, cal-ibrators and controls 
were diluted 1 : 4 with PBS buffer. 
 
Instrumentation  
The Tecan Miniprep 75, Columbus plate washer and Sunrise plate 
reader (all manufactured by Tecan Group Ltd., Switzerland) were 
used for this study. 
 
Immunoassay procedure  
Every fortified blood sample was prepared in duplicate, and every 
sample was pipetted into two separate wells providing four results for 
each concentration. Ten microliters of calibra-tor, control or fortified 
blood were added into each appropri-ate well. The samples were 
added in the order of increasing concentration. The immunoassay 
was carried out according to the Immunalysis protocol (10). The 
absorbance was mea-sured at 450 nm using the plate reader. The 
absorbance is in-versely proportional to the concentration of the drug. 
Sensitivity, precision and cross-reactivity data were provided by 
Immunalysis. 
 
 
 
Results and discussion 
 
In forensic toxicology, it is important to keep up with emerging drugs 
of abuse and be aware of the drugs that give us a positive response 
at the screening step. It is crucial that laboratory confir-mation 
methods are capable of matching the range of drugs that can be 
detected at the screening step in order for the screen to be a valuable 
test. This study found that these benzodiazepines do cross react with 
the Immunalysis® Benzodiazepine ELISA kit (Table I). When the 
calibrators were made up in PBS buffer, the cross-reactivity was 113, 
109, 104, 97, 104 and 86% for phenaza-pam, etizolam, pyrazolam, 
flubromazepam, diclazepam and delor-azepam, respectively. When 
the calibrators were prepared in blank blood, the cross-reactivity was 
90, 107, 86, 84, 79 and 80% for phe-nazepam, etizolam, pyrazolam, 
flubromazepam, diclazepam and delorazepam, respectively. All 
results were considered acceptable with a percentage of covariation 
below 15. The cross-reactivity of diclazepam’s other metabolites, 
lorazepam and lormetazepam, was not determined as these details 
are included in the manufacture’s instruction manual. The cross-
reactivity of lorazepam is stated as 90% at a concentration of 50 
pg/well and 85% at a concentration of 100 pg/well. The cross-
reactivity of lormetazepam is stated as 120% at a concentration of 
500 pg/well. 
 
Case study 
 
This case study describes the death of a 20-year-old male who had 
been diagnosed with a psychotic disorder. He had a history 
 
 
Table I  
Cross-Reactivity with PBS Buffer and Blank Blood Calibrators 
 
Drug Concentration Calibrators in SD Calibrators in SD 
 (ng/mL) PBS buffer, % (n = 4) blank blood, % (n = 4) 
  cross-reactivity  cross-reactivity  
      
Phenazepam 5 107 0.01 96 0.01 
 10 110 0.02 109 0.03 
 100 143 0.01 84 0.01 
 300 93 0.02 69 0.02 
Etizolam 5 111 0.03 100 0.03 
 10 96 0.05 96 0.06 
 100 84 0.01 126 0.01 
 300 143 0.01 107 0.01 
Pyrazolam 5 90 0.06 94 0.10 
 10 75 0.04 88 0.13 
 100 139 0.03 82 0.03 
 300 111 0.02 81 0.01 
Flubromazepam 5 98 0.08 91 0.01 
 10 103 0.11 98 0.03 
 100 82 0.02 75 0.02 
 300 105 0.01 73 0.01 
Diclazepam 5 106 0.08 85 0.04 
 10 91 0.07 98 0.03 
 100 122 0.04 72 0.04 
 300 95 0.00 62 0.01 
Delorazepam 5 89 0.09 87 0.08 
 10 90 0.07 93 0.05 
 100 72 0.03 70 0.03 
 300 93 0.01 69 0.01 
      
 
 
of drug abuse, in particular legal drugs, which he appeared to be 
purchasing from websites. At the time of his death, he was pre-
scribed lymecycline, fluoxetine, pregabalin and zuclopenthixol. The 
deceased was found face down in bed. There were various powders, 
tablets and ‘legal high’ packets found inside his house. The 
deceased’s blood triggered a positive ELISA response using the 
Immunalysis® Benzodiazepine ELISA kit. The confirma-tion tests in 
this case were carried out by using the 1200 series HPLC system 
(Agilent Technologies, Santa Clara, CA, USA) equipped with the 
Agilent 6410 Triple Quad LC/MS System (Agilent Technologies). The 
etizolam and pyrazolam methods had a limit of detection of 0.0025 
mg/L and a limit of quantita-tion of 0.005 mg/L. The sample was 
analyzed for 10 benzodiaze-pines including diazepam, 
desmethyldiazepam, oxazepam, temazepam, lorazepam, 7-
aminoflunitrazepam, nitrazepam, chlorodiazepoxide, phenazepam 
and an etizolam screen. Etizolam was confirmed at a concentration of 
0.01 mg/L. A test for pyrazolam was also carried out due to 
pyrazolam tablets being present during the study. Pyrazolam was 
found in the blood at a concentration of 0.07 mg/L. All of the other 
benzodiazepines mentioned were negative. This suggests that the 
Immunalysis® Benzodiazepine ELISA kit will identify etizo-lam and/or 
pyrazolam in postmortem blood in real cases. 
 
Conclusion 
 
This study has illustrated that all six drugs tested have good cross-
reactivity with the Immunalysis® Benzodiazepine ELISA kit. The 
benzodiazepine drug group is vast and has the potential for many 
uncontrolled drugs to be added to the legal market. As the prev-
alence of these drugs is unknown, it is critical that confirmatory 
toxicological methods expand to include the newer emerging drugs in 
order to stay relevant. Including these new drugs in rou-tine analysis 
will allow the prevalence of this drugs to be monitored. 
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